The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during ...

A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary prevention and the ...

HELSINKI, Finland — The pros and cons of early vs late initiation of a direct oral anticoagulant (OAC) after acute ischemic stroke in the setting of atrial fibrillation (AF) for secondary prevention ...

Early on in the COVID-19 pandemic, patient presentations and autopsy reports made it abundantly clear that abnormal coagulation and multiorgan clotting were key signatures of this disease. Interim ...

Changes in the hemostatic system and chronic hemostatic activation are frequently observed in patients with cancer, even in the absence of venous thromboembolism (VTE). VTE is a leading cause of death ...

Atherosclerotic peripheral arterial disease is associated with an increased risk of myocardial infarction, stroke, and death from cardiovascular causes. Antiplatelet drugs reduce this risk, but the ...

MADRID -- Stopping oral anticoagulation after successful ablation for atrial fibrillation (AF, Afib) improved outcomes for patients without documented recurrence, the randomized ALONE-AF trial showed.

To the Editor: Douketis et al. (Aug. 27 issue) 1 report on the results of the Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive ...

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. Primary prevention with pharmacologic agents (or mechanical methods, if anticoagulants are ...